Great information listed below that provides actua
Post# of 647
Posted On: 12/29/2013 11:24:37 PM
Great information listed below that provides actual due diligence about IFUS.
keep in mind the biggest problem in Pink stocks is dilution, no products, and no sales.
This is the only pink sheet stock I know of that has held the AS unchanged since 2010 (that was verified at OTC and the Nevada Sec of state's office recently). That is only possible if they do not need to sell shares, and have not sold shares to pay the bills. That is only possible if they have sales and gross profits above the cost of goods sold, that are high enough to pay the rest of the bills.
WE know they have 3 verified product lines with real sales. We know they must have at least 20-30 distributors now (my by count which I have verified).
We know the products work better than anything else on the market, at least I know this for a fact.
That means the company has operating costs under control, and is at least keeping them at or below gross profit at a minimum as they grow sales. I doubt IFUS operates on credit, and thus must be surviving on cash flow from sales. They could NOT deliver products in 48 hours off the shelf like we have seen, with out inventory paid for in advance with cash sitting in their inventory. So this means they have inventory.
That means that as sales and revenue grows, the company must be seeing growth in gross profit dollars. Increased growth profit dollars can be used to pay off debt (for instance the loan against the 64 acre plant site land, if there is any loan balance left?). Increased growth profit dollars can be used to increase sales and marketing, with out borrowing money, to increase revenues.
A real company, with real brick and mortar and land (64 acres) and intellectual property and patents and products and sales that is growing revenue and is not borrowing money against public shares, that has a tiny market cap like IFUS has, is one of the best buy and hold growth stocks in the stock market, because it is so way undervalued.
All IFUS needs is to close one major bagasse or Mastic Blast [/b]contract deal, and PR the deal, after the check clears the bank, to send the stock price to a dime because it is undervalued.
The rally to .04 this year confirms how undervalued it is at this price. I will not sell my shares until I think IFUS is fully valued. And then I may only sell 10%/year to avoid a huge tax bill.
I am still a buyer of IFUS shares here when I have the cash.
There are many other OTC and pink stocks with market caps and stock prices that are 10 to 30 times the price of IFUS shares and are 10 to 30 times the IFUS market cap, that have no sales at all.
Many Nasdaq and Amex board Biotech stocks have 10 to 40 times the market cap of IFUS with no sales and years of dilution facing them and FDA drug trial costs facing them. Some high tech energy related technology stocks I follow that have sales are still selling shares to cover 5 to 20 million dollar per year losses because they do not control R&D and marketing cost over runs. Some major ones, one was a darling of wallstreet recently with US-DOE funding that had a billion dollar IPO for a new patented Li-ion battery already wiped out investors in under 3 years with a bankruptcy, while IFUS, since 2009 is still in business and growing.
keep in mind the biggest problem in Pink stocks is dilution, no products, and no sales.
This is the only pink sheet stock I know of that has held the AS unchanged since 2010 (that was verified at OTC and the Nevada Sec of state's office recently). That is only possible if they do not need to sell shares, and have not sold shares to pay the bills. That is only possible if they have sales and gross profits above the cost of goods sold, that are high enough to pay the rest of the bills.
WE know they have 3 verified product lines with real sales. We know they must have at least 20-30 distributors now (my by count which I have verified).
We know the products work better than anything else on the market, at least I know this for a fact.
That means the company has operating costs under control, and is at least keeping them at or below gross profit at a minimum as they grow sales. I doubt IFUS operates on credit, and thus must be surviving on cash flow from sales. They could NOT deliver products in 48 hours off the shelf like we have seen, with out inventory paid for in advance with cash sitting in their inventory. So this means they have inventory.
That means that as sales and revenue grows, the company must be seeing growth in gross profit dollars. Increased growth profit dollars can be used to pay off debt (for instance the loan against the 64 acre plant site land, if there is any loan balance left?). Increased growth profit dollars can be used to increase sales and marketing, with out borrowing money, to increase revenues.
A real company, with real brick and mortar and land (64 acres) and intellectual property and patents and products and sales that is growing revenue and is not borrowing money against public shares, that has a tiny market cap like IFUS has, is one of the best buy and hold growth stocks in the stock market, because it is so way undervalued.
All IFUS needs is to close one major bagasse or Mastic Blast [/b]contract deal, and PR the deal, after the check clears the bank, to send the stock price to a dime because it is undervalued.
The rally to .04 this year confirms how undervalued it is at this price. I will not sell my shares until I think IFUS is fully valued. And then I may only sell 10%/year to avoid a huge tax bill.
I am still a buyer of IFUS shares here when I have the cash.
There are many other OTC and pink stocks with market caps and stock prices that are 10 to 30 times the price of IFUS shares and are 10 to 30 times the IFUS market cap, that have no sales at all.
Many Nasdaq and Amex board Biotech stocks have 10 to 40 times the market cap of IFUS with no sales and years of dilution facing them and FDA drug trial costs facing them. Some high tech energy related technology stocks I follow that have sales are still selling shares to cover 5 to 20 million dollar per year losses because they do not control R&D and marketing cost over runs. Some major ones, one was a darling of wallstreet recently with US-DOE funding that had a billion dollar IPO for a new patented Li-ion battery already wiped out investors in under 3 years with a bankruptcy, while IFUS, since 2009 is still in business and growing.
(0)
(0)